Targeting mitochondria by α-tocopheryl succinate kills neuroblastoma cells irrespective of MycN oncogene expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• MycN oncogene amplification is a hallmark of aggressive neuroblastoma, a common childhood cancer.
• The role of MycN in tumor cell survival and drug resistance remains controversial, as its downregulation can decrease sensitivity to chemotherapy.
• Conventional treatments like cisplatin and doxorubicin show limited efficacy in MycN-amplified neuroblastomas.

Purpose of the Study:

• To investigate the efficacy of alpha-tocopheryl succinate (α-TOS), a vitamin E analogue, against neuroblastoma cells.
• To determine if α-TOS can overcome MycN-mediated drug resistance.
• To elucidate the mechanism of action of α-TOS in neuroblastoma cells.

Main Methods:

• Utilized neuroblastoma cell lines with varying MycN expression levels (overexpressed and downregulated).
• Administered α-TOS and assessed its effect on cell viability and apoptosis.
• Measured intracellular calcium (Ca2+) levels, mitochondrial calcium buffering capacity, and mitochondrial permeability transition.
• Investigated the role of calcium in α-TOS-induced cell death.

Main Results:

• α-TOS induced apoptotic cell death in neuroblastoma cells irrespective of their MycN expression status.
• α-TOS triggered rapid cytosolic Ca2+ influx and impaired mitochondrial Ca2+ buffering capacity.
• Mitochondrial calcium overload sensitized cells to apoptosis, which was prevented by inhibiting Ca2+ accumulation or chelating cytosolic Ca2+.
• α-TOS demonstrated efficacy even in cells with MycN downregulation, suggesting a mechanism independent of MycN's direct influence on drug sensitivity.

Conclusions:

• Mitochondria-targeted therapy with α-TOS is a promising strategy for treating aggressive neuroblastomas.
• α-TOS effectively eliminates neuroblastoma cells by inducing mitochondrial calcium dysregulation and apoptosis.
• This approach may overcome therapeutic resistance associated with MycN amplification and dormant apoptotic pathways.